AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19103732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of epirubicin, 60 mg/m(2) (EC)
Number of subjects: 777
Study 19103732 — intervention group
Group type: COMPARATOR
Intervention: Classical oral cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 777
Study 16384764 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body skin examinations
Number of subjects: 16383
Study 12771114 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate, n = 8506)
Number of subjects: 16608
Study 12771114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8102)
Number of subjects: 16608
Study 12771114 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study 10720165 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (43-57 g/d, 12.5% of energy from walnuts)
Number of subjects: 40
Study 10720165 — intervention group
Group type: COMPARATOR
Intervention: Reference diet
Number of subjects: 40
Study 9352475 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g inositol
Number of subjects: 7
Study 9352475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8269446 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8
Study 8269446 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 8
Study 8269446 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 40 mg
Number of subjects: 8
Study 8269446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3985604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (50 mg/kg of body weight to a maximum of 2 g)
Number of subjects: 63
Study 3985604 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (60 mg/kg of body weight to a maximum of 2.4 g)
Number of subjects: 63
Study 3985604 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (50 mg/kg of body weight to a maximum of 2 g daily for 3 days)
Number of subjects: 63
Study 30907345 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and behavioral intervention
Number of subjects: 60
Study 30907345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 60
Study 30907345 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (psychological and behavioral intervention + biofeedback)
Number of subjects: 60
Study 30907345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30276476 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/day for 3 days)
Number of subjects: 8
Study 30276476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30276476 — intervention group
Group type: COMPARATOR
Intervention: Curcumin and Placebo
Number of subjects: 8
Study 25747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (2 bouts of 200kcal each)
Number of subjects: 10
Study 25747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cycling (400kcal)
Number of subjects: 10
Study 25747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running (400kcal)
Number of subjects: 10
Study 25747467 — intervention group
Group type: COMPARATOR
Intervention: Control session (non-exercise day)
Number of subjects: 10
Study 25747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise
Number of subjects: 10
Study 25747467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10
Study 25441521 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically amplified stethoscope (Littmann 3200, 3M)
Number of subjects: 40
Study 25441521 — intervention group
Group type: COMPARATOR
Intervention: Traditional stethoscope (Littmann Cardiology III; 3M)
Number of subjects: 40
Study 21935584 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (GlaxoSmithKline Biologicals), 2 doses 42-56 days apart, N=371
Number of subjects: 494
Study 21935584 — intervention group
Group type: COMPARATOR
Intervention: MMR + V (Priorix™ and Varilrix™), 1 dose each administered simultaneously, followed by another MMR vaccination 42-56 days later, N=123
Number of subjects: 494
Study 21144030 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach supervised intervention program targeting jump-landing technique, performed 2 times a week for 3 months during warm-up (5-10 min).
Number of subjects: 24
Study 21144030 — intervention group
Group type: COMPARATOR
Intervention: Normal training routine (Control group).
Number of subjects: 24
Study 17604960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anthracycline treatment
Number of subjects: 56
Study 17604960 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 age-matched normal controls)
Number of subjects: 56
Study 16139696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two‐implant overdentures (IOD; n=54)
Number of subjects: 102
Study 16139696 — intervention group
Group type: COMPARATOR
Intervention: New mandibular conventional complete dentures (CD; n=48)
Number of subjects: 102
Study 12474023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin Na+
Number of subjects: 120
Study 12474023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10425409 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg droperidol
Number of subjects: 100
Study 10425409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 100
Study 10425409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7750331 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid inhaler (n = 41)
Number of subjects: 100
Study 7750331 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo inhaler (n = 59)
Number of subjects: 100
Study 7750331 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid inhaler (n = 41) with strong airway sensations
Number of subjects: 100
Study 7750331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at 6 months
Number of subjects: 100
Study 2274996 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 2274996 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study 7357254 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 4 km/h for 1 minute
Number of subjects: 26
Study 7357254 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 6 km/h for 1 or 2 minutes
Number of subjects: 26
Study 7357254 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 4 km/h for 1 minute on a 10% slope
Number of subjects: 26
Study 7357254 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise test
Number of subjects: 26
Study 30369433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg/kg ketamine
Number of subjects: 55
Study 30369433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2-mg/kg ketamine
Number of subjects: 55
Study 30369433 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 55
Study 26732025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk fermented with Lactobacillus paracasei CBA L74
Number of subjects: 377
Study 26732025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice fermented with Lactobacillus paracasei CBA L74
Number of subjects: 377
Study 26732025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 377
Study 25451556 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs/LC n‐3 PUFAs intake (fish/shellfish, fish oil supplements, perilla oils) for 24 months
Number of subjects: 205
Study 25451556 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to reduce consumption of fats/oils
Number of subjects: 205
Study 25451556 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs/LC n‐3 PUFAs intake
Number of subjects: 205
Study 24195916 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus optimal medical management
Number of subjects: 0
Study 24195916 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management alone
Number of subjects: 0
Study 21455075 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel device
Number of subjects: 60
Study 21455075 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 60
Study 21455075 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study 19815581 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 1199
Study 19815581 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 1199
Study 19815581 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 1199
Study 18704870 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-medical intervention (EG 1)
Number of subjects: 206
Study 18704870 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy module (EG 2)
Number of subjects: 206
Study 18704870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 206
Study 16012177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) regimens
Number of subjects: 391
Study 12474114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.6 mg and 0.85 mg DMT/kg body weight)
Number of subjects: 18
Study 12474114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10095919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibacterial drugs for uncomplicated pneumonia
Number of subjects: 0
Study 10095919 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting regimen for nosocomial or hospital pneumonia
Number of subjects: 0
Study 8861134 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary magnesium (315 mg/d)
Number of subjects: 13
Study 8861134 — intervention group
Group type: COMPARATOR
Intervention: Low dietary magnesium (115 mg/d)
Number of subjects: 13
Study 8861134 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary boron (3.23 mg/d)
Number of subjects: 13
Study 8861134 — intervention group
Group type: COMPARATOR
Intervention: Low dietary boron (0.23 mg/d)
Number of subjects: 13
Study 2101950 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via metered-dose inhaler (MDI)
Number of subjects: 14
Study 2101950 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via spacer
Number of subjects: 14
Study 7380993 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 9
Study 7380993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Metoclopramide (10 mg)
Number of subjects: 9
Study 7380993 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) during dopamine infusion
Number of subjects: 9
Study 7380993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29807495 — intervention group
Group type: EXPERIMENTAL
Intervention: Latina Breast Cancer Survivorship Intervention (telephone-based, 3 education sessions weekly, 6 support calls)
Number of subjects: 40
Study 29807495 — intervention group
Group type: COMPARATOR
Intervention: Support and early education (intervention group)
Number of subjects: 40
Study 29807495 — intervention group
Group type: COMPARATOR
Intervention: Support and delayed education (control group)
Number of subjects: 40
Study 26205775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools with policy changes and portable equipment
Number of subjects: 1582
Study 26205775 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1582
Study 24854628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5414
Study 24854628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5414
Study 24854628 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCA1 R219K variant presence
Number of subjects: 5414
Study 23248895 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Number of subjects: 130
Study 23248895 — intervention group
Group type: COMPARATOR
Intervention: Sonic control toothbrush (Philips Sonicare Essence 5500)
Number of subjects: 130
Study 20636719 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific walking training plus targeted strength training three times per week over 10 weeks
Number of subjects: 0
Study 20636719 — intervention group
Group type: COMPARATOR
Intervention: Task-specific walking training
Number of subjects: 0
Study 18543584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen tablets (400 mg)
Number of subjects: 20
Study 18543584 — intervention group
Group type: COMPARATOR
Intervention: Racemic ibuprofen tablets (400 mg)
Number of subjects: 20
Study 16633363 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate consolidation with high-dose chemotherapy and hematopoietic support
Number of subjects: 69
Study 16633363 — intervention group
Group type: COMPARATOR
Intervention: Observation with delayed consolidation
Number of subjects: 69
Study 12941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (C225 and ABX‐EGF) and tyrosine kinase inhibitors (ZD1839 and OSI‐774)
Number of subjects: 0
Study 12941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of farnesyl transferase (R115777 and SCH66336)
Number of subjects: 0
Study 12941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of vascular growth factor receptor (bevacizumab and PTK787)
Number of subjects: 0
Study 12941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase‐2 inhibitors in colorectal cancer and STI571 in GI stromal tumors
Number of subjects: 0
Study 12941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents administered alone or in combination with standard therapies
Number of subjects: 0
Study 10532418 — intervention group
Group type: EXPERIMENTAL
Intervention: TdT‐mediated dUTP‐biotin nick‐end labeling (TUNEL) method
Number of subjects: 25
Study 10532418 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of bcl‐2 protein
Number of subjects: 25
Study 10532418 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of p53 protein
Number of subjects: 25
Study 10532418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67 antibody for cell proliferative activity
Number of subjects: 25
Study 10532418 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic cell distribution in GB
Number of subjects: 25
Study 8983318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5mg and 5mg
Number of subjects: 30
Study 8983318 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10mg and 20mg
Number of subjects: 30
Study 1953228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg twice a day for 8 weeks
Number of subjects: 82
Study 1953228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg twice a day for an additional 8 weeks
Number of subjects: 82
Study 7347361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supervised education class
Number of subjects: 112
Study 7347361 — intervention group
Group type: COMPARATOR
Intervention: Gastroenterologist appointments
Number of subjects: 112
Study 30938568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B plus GeneTimeÂ® (observation group)
Number of subjects: 100
Study 30938568 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B alone (control group)
Number of subjects: 100
Study 27561307 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video demonstrating pain behavior
Number of subjects: 40
Study 27561307 — intervention group
Group type: COMPARATOR
Intervention: Instructional video demonstrating a stoic response
Number of subjects: 40
Study 27561307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor task
Number of subjects: 40
Study 26118949 — intervention group
Group type: EXPERIMENTAL
Intervention: IMH-HB EHS services (n = 75)
Number of subjects: 152
Study 26118949 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (n = 77)
Number of subjects: 152
Study 23546628 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formula
Number of subjects: 740
Study 23546628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 21821513 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody resistive warming
Number of subjects: 70
Study 21821513 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming
Number of subjects: 70
Study 19726912 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot pet-assisted program
Number of subjects: 32
Study 18006923 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic activity, 60 min/d, 6 days/wk
Number of subjects: 184
Study 18006923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 184
Study 14739815 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg neostigmine
Number of subjects: 80
Study 14739815 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg neostigmine
Number of subjects: 80
Study 14739815 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg neostigmine
Number of subjects: 80
Study 14739815 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 14739815 — intervention group
Group type: EXPERIMENTAL
Intervention: All neostigmine groups (75, 150, 300 microg)
Number of subjects: 80
Study 14739815 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 11281234 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine‐GITS
Number of subjects: 30
Study 11281234 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil‐SR
Number of subjects: 30
Study 9567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Middleton's manoeuvre
Number of subjects: 80
Study 9567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine palpation
Number of subjects: 80
Study 9567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Castell's manoeuvre
Number of subjects: 80
Study 9567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nixon's manoeuvre
Number of subjects: 80
Study 9567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Traube's space percussion
Number of subjects: 80
Study 7943768 — intervention group
Group type: EXPERIMENTAL
Intervention: Belscope angulated straight blade
Number of subjects: 98
Study 7943768 — intervention group
Group type: COMPARATOR
Intervention: Wisconsin blade
Number of subjects: 98
Study 7943768 — intervention group
Group type: EXPERIMENTAL
Intervention: All blades used in Study 1 and Study 2
Number of subjects: 98
Study 3108131 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (500 micrograms intravenously)
Number of subjects: 4
Study 30767647 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelonet Plus (JP) dressing
Number of subjects: 99
Study 30767647 — intervention group
Group type: COMPARATOR
Intervention: UrgoTul (UT) dressing
Number of subjects: 99
Study 27914297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin add-on therapy
Number of subjects: 73
Study 27914297 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without DPP-4 inhibitors
Number of subjects: 73
Study 25061034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) and stretching exercise
Number of subjects: 0
Study 25061034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular electrical stimulation (IMS) and stretching exercise
Number of subjects: 0
Study 25061034 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 0
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug events (ADEs)
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drug-related problems (DRPs)
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious ADEs
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected ADEs
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal tract involvement in ADEs
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems with administration and dosing of medicine
Number of subjects: 4032
Study 23093040 — intervention group
Group type: EXPERIMENTAL
Intervention: DRPs related to anti-infectives
Number of subjects: 4032
Study 21314913 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Therapeutic Dinosaur Programme delivered in small groups for 2 hours/week for 18 weeks
Number of subjects: 240
Study 21314913 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 240
Study 21314913 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Therapeutic Dinosaur Programme
Number of subjects: 240
Study 18392557 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with careful monitoring of INR
Number of subjects: 0
Study 18392557 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16545702 — intervention group
Group type: EXPERIMENTAL
Intervention: LactoSorb (n = 18)
Number of subjects: 64
Study 16545702 — intervention group
Group type: EXPERIMENTAL
Intervention: BioSorb (n = 18)
Number of subjects: 64
Study 16545702 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta (n = 18)
Number of subjects: 64
Study 16545702 — intervention group
Group type: COMPARATOR
Intervention: Titanium osteosynthesis (control group D: n = 15)
Number of subjects: 64
Study 15601464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (HD)
Number of subjects: 83
Study 11346448 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexyx Neurotherapy System (FNS)
Number of subjects: 12
Study 11346448 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 12
Study 9236644 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version
Number of subjects: 243
Study 10155208 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated coronary stents
Number of subjects: 0
Study 10155208 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed deep anticoagulation
Number of subjects: 0